In a report entitled “Questionable Billing for Medicare Independent Diagnostic Testing Facility Services,” the OIG discusses its examination of geographic patterns in Medicare independent diagnostic testing facility (IDTF) billing, in which it reviewed 2009 claims by Core Based Statistical Area (CBSA). According to the OIG, 20 high-utilization CBSAs with 2.2% of the total

The OIG has created a “spotlight page” on its website to highlight its reports and findings involving the Medicaid drug rebate program. The page features comparisons of drug spending under Medicaid and Medicare Part D, manufacturer compliance with Average Manufacturer Price reporting requirements, manufacturer development of new versions of existing brand-name drugs to minimize rebate

The OIG has created a “spotlight page” on its website that compiles information on previous OIG investigations involving independent diagnostic testing facilities (IDTFs) — Medicare providers that furnish diagnostic services independent from a physician’s office or hospital. According to the OIG, “IDTF services have historically been vulnerable to abuse,” and thus have been a topic